{"id":7151,"date":"2025-04-28T11:10:04","date_gmt":"2025-04-28T09:10:04","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=publication&p=7151"},"modified":"2025-04-28T21:13:42","modified_gmt":"2025-04-28T19:13:42","slug":"comparative-effectiveness-and-safety-of-tislelizumab-versus-other-anti-pd-l1-agents-in-first-and-subsequent-lines-in-locally-advanced-or-metastatic-non-small-cell-lung-cancer-syste","status":"publish","type":"publication","link":"https:\/\/beonemedaffairs.com\/us\/publication\/comparative-effectiveness-and-safety-of-tislelizumab-versus-other-anti-pd-l1-agents-in-first-and-subsequent-lines-in-locally-advanced-or-metastatic-non-small-cell-lung-cancer-syste\/","title":{"rendered":"Comparative effectiveness and safety of tislelizumab versus other anti\u2013PD-(L)1 agents in first- and subsequent lines in locally advanced or metastatic non\u2013small cell lung cancer: Systematic literature review and network meta-analysis"},"content":{"rendered":"","protected":false},"template":"","post-tag":[],"class_list":["post-7151","publication","type-publication","status-publish","hentry","disease_state-non-small-cell-lung-cancer","molecule-tislelizumab"],"acf":[],"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication\/7151","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=7151"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=7151"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}